Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer.

导出 OA

翻译打印收藏纠错

作者： Santiago,Cabezas-Camarero ^[1] ; Salomé,Merino-Menéndez ^[2] ; María Nieves,Cabrera-Martín ^[3] ; Miguel J,Sotelo ^[4] ; José Carlos,Plaza-Hernández ^[5] ; Farzin,Falahat ^[6] ; María Cruz,Iglesias-Moreno ^[7] ; Pedro,Pérez-Segura ^[8]

作者单位： Head and Neck Cancer, Neuro-Oncology and Genetic Counseling Unit, Medical Oncology Department, Instituto de Investigación Sanitaria San Carlos, Madrid 28040, Spain. ^[1] Radiology Department, Clinico San Carlos University Hospital, Madrid 28040, Spain. ^[2] Nuclear Medicine Department, Clinico San Carlos University Hospital, Madrid 28040, Spain. ^[3] Medical Oncology Department, Aliada Cancer Center, San Isidro 15036, Peru. ^[4] Medical Oncology Department, San Felipe Hospital, Jesús María 15072, Peru. ^[5] Medical Oncology Department, María Auxiliadora Hospital, San Juan de Miraflores 15801, Peru. ^[6] Pathology Department, Clinico San Carlos University Hospital, Madrid 28040, Spain. ^[7] Department of Craniomaxilofacial Surgery, Clinico San Carlos University Hospital, Madrid 28040, Spain. ^[8] Department of Otolaryngology-Head and Neck Surgery, Clinico San Carlos University Hospital, Madrid 28040, Spain. ^[9]

关键词 anti-programmed cell death protein 1 carboplatin chemoimmunotherapy head and neck cancer paclitaxel pembrolizumab

DOI 10.3892/ol.2022.13623

PMID 36589672

发布时间 2023-01-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交